Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors

Molecular and Cellular Proteomics

Volumn 3, Issue 5, 2004, Pages 490-500

  Brehmer, Dirk ^a   Godl, Klaus ^a   Zech, Birgit ^a   Wissing, Josef ^a   Daub, Henrik ^a  

^a Axxima Pharmaceuticals AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMINOPROPYL) 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 AMINOPROPYL) 6,7,8,9 TETRAHYDROPYRIDOL[1,2 A]INDOL 3 YL] 3 (1 METHYLINDOL 3 YL)MALEIMIDE; 2 [1 (3 AMINOPROPYL)INDOL 3 YL] 3 (1 METHYLINDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ADENOSINE KINASE; BISINDOLYLMALEIMIDE; CYCLIN DEPENDENT KINASE 2; LIGAND; MALEIMIDE DERIVATIVE; OXIDOREDUCTASE; PROTEIN KINASE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RIBOSOME PROTEIN; S6 KINASE; STAUROSPORINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; CORRELATION FUNCTION; CRYSTAL STRUCTURE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMOBILIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; PROTEOMICS;

ANIMALS; CDC2-CDC28 KINASES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, AFFINITY; COS CELLS; CYCLIN-DEPENDENT KINASE 2; ENZYME INHIBITORS; HELA CELLS; HUMANS; INDOLES; MALEIMIDES; MODELS, MOLECULAR; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; QUINONE REDUCTASES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 2442455834     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M300139-MCP200     Document Type: Article

References (34)

1. Newton, A. C. (2001) Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 101, 2353-2364
2. Dempsey, E. C., Newton, A. C., Mochly-Rosen, D., Fields, A. P., Reyland, M. E., Insel, P. A., and Messing, R. O. (2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L429-1-438
3. Goekjian, P. G., and Jirousek, M. R. (1999) Protein kinase C in the treatment of disease: signal transcluction pathways, inhibitors, and agents in development. Curr. Med. Chem. 6, 877-903
4. Barry, O. P., and Kazanietz, M. G. (2001) Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr. Pharm. Des. 7, 1725-1744
5. Vlahos, C. J., McDowell, S. A., and Clerk, A. (2003) Kinases as therapeutic targets for heart failure. Nat. Rev. Drug Discov. 2, 99-113
6. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771-15781
7. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
8. Coultrap, S. J., Sun, H., Tanner, T. E., Jr., and Machu, T. K. (1999) Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor. J. Pharmacol. Exp. Ther. 290, 76-82
9. Lingameneni, R., Vysotskaya, T. N., Duch, D. S., and Hemmings, H. C., Jr. (2000) Inhibition of voltage-dependent sodium channels by Ro 31-8220, a "specific" protein kinase C inhibitor. FEBS Lett. 473, 265-268
10. Knockaert, M., Gray, N., Damiens, E., Chang, Y. T., Grellier, P., Grant, K., Fergusson, D., Mottram, J., Soete, M., Dubremetz, J. F., Le Roch, K., Doerig, C., Schultz, P., and Meijer, L. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 7, 411-422
11. Lolli, G., Thaler, F., Valsasina, B., Roletto; F., Knapp, S., Uggeri, M., Bachi, A., Matafora, V., Storici, P., Stewart, A., Kalisz, H. M., and Isacchi, A. (2003) Inhibitor affinity chromatography: profiling the specific reactivity of the proteome with immobilized molecules. Proteomics 3, 1287-1298
12. Ding, S., Wu, T. Y., Brinker, A., Peters, E. C., Hur, W., Gray, N. S., and Schultz P. G. (2003) Synthetic small molecules that control stem cell fate. Proc. Natl. Acad. Sci. U. S. A. 100, 7632-7637
13. Brown, D., and Superti-Furga, G. (2003) Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8, 1067-1077
14. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci U. S. A. 100, 15434-15439
15. Daub, H., Blencke, S., Habenberger, P., Kurtenbach, A., Dennenmoser, J., Wissing, J., Ullrich, A., and Cotten, M. (2002) Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J. Virol. 76, 8124-8137
16. Spychala, J., Datta, N. S., Takabayashi, K., Datta, M., Fox, I. H., Gribbin, T., and Mitchell, B. S. (1996) Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases. Proc. Natl. Acad. Sci. U. S. A. 93, 1232-1237
17. Yamada, E., Tsujikawa, K., Itoh, S., Kameda, Y., Kohama, Y., and Yamamoto, H. (2000) Molecular cloning and characterization of a novel human STE20-like kinase, hSLK. Biochim. Biophys. Acta 1495, 250-262
18. Blencke, S., Ullrich, A., and Daub, H. (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278, 15435-15440
19. Lawrie, A. M., Noble, M. E., Tunnah, P., Brown, N. R., Johnson, L. N., and Endicott, J. A. (1997) Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4, 796-801
20. Underwood, K. W., Parris, K. D., Federico, E., Mosyak, L., Czerwinski, R. M., Shane, T., Taylor, M., Svenson, K., Liu, Y., Hsiao, C. L., Wolfrom, S., Maguire, M., Malakian, K., Telliez, J. B., Lin, L. L., Kriz, R. W., Seehra, J., Somers, W. S., and Stahl, M. L. (2003) Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. Structure 11, 627-636
21. Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zhao, H., and Morgenstern, K. A. (1999) Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure. Fold. Des. 7, 651-661
22. Knox, R. J., Burke, P. J., Chen, S., and Kerr, D. J. (2003) CB 1954: From the Walker tumor to NQO2 and VDEPT. Curr. Pharm. Des. 9. 2091-2104
23. Long, D. J., Iskander, K., Gaikwad, A., Arin, M., Roop, D. R., Knox, R., Barrios, R., and Jaiswal, A. K. (2002) Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem. 277, 46131-46139
24. Wu, K., Knox, R., Sun, X. Z., Joseph, P., Jaiswal, A. K., Zhang, D., Deng, P. S., and Chen, S. (1997) Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 347, 221-228
25. Gorntsyan, A., DiDomenico, S., Lee, C. H., Matulenko, M. A., Kim, K., Kowaluk, E. A., Wismer, C. T., Mikusa, J., Yu, H., Kohlhaas, K., Jarvis, M. F., and Bhagwat, S. S. (2002) Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors. J. Med. Chem. 45, 3639-3648
26. Ugarkar, B. G., Castellino, A. J., Dare, J. M., Kopcho, J. J., Wiesner, J. B., Schanzer, J. M., and Erion, M. D. (2000) Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. J. Med. Chem. 43, 2894-2905
27. Ugarkar, B. G., DaRe, J. M., Kopcho, J. J., Browne, C. E., III, Schanzer, J. M., Wiesner, J. B., and Erion, M. D. (2000) Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J. Med. Chem. 43, 2883-2893
28. Sabourin, L. A., and Rudnicki, M. A. (1999) Induction of apoptosis by SLK, a Ste20-related kinase. Oncogene 18, 7566-7575
29. Sabourin, L. A., Tamai, K., Seale, P., Wagner, J., and Rudnicki, M. A. (2000) Caspase 3 cleavage of the Ste20-related kinase SLK releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region. Mol. Cell. Biol. 20, 684-696
30. Roux, P. P., Richards, S. A., and Blenis, J. (2003) Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol. Cell. Biol. 23, 4796-4804
31. Dancey, J., and Sausville, E. A. (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2, 296-313
32. Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. (2003) Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol. 7, 490-495
33. Gygi, S. P., Corthals, G. L., Zhang, Y., Rochon, Y., and Aebersold, R. (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl. Acad. Sci. U. S. A. 97, 9390-9395
34. Wu, C. C., MacCoss, M. J., Howell, K. E., and Yates, J. R., III (2003) A method for the comprehensive proteomic analysis of membrane proteins. Nat. Biotechnol. 21, 532-538